U.S. Specialized REITs Stock News

Li Auto deliveries put fresh focus on the stock ahead of earnings Li Auto (LI) just released its July delivery update, reporting 30,468 vehicles for the month and 1,764,155 vehicles total. This operational snapshot comes as investors watch the upcoming earnings release. See our latest analysis for Li Auto. Despite the fresh delivery update, Li Auto’s share price tells a mixed story, with a 1 day share price return of 2.05%, a year to date share price return down 24.93%, and a 1 year...

Blue Bird stock has delivered a very strong 225.9% return over the past three years, yet the current market pricing lines up with a high overall value score while traditional earnings multiples still screen the shares as overvalued. That mix leaves investors weighing solid valuation checks against a richer headline multiple. Blue Bird's 225.9% return over three years highlights how much optimism has already been built into the share price. Expectations for sustained demand and cash...

Tower Semiconductor stock has delivered very strong gains over the past few years, yet the broad valuation checks currently point to a company that screens as expensive rather than a clear bargain. Over the past 5 years, Tower Semiconductor has returned about 7.9x, which means any new investor today is paying a price that already reflects a very strong run. Recent record revenue and profitability can support high expectations for future earnings, while any disappointment against those higher...

Apollo Global Management has delivered a 137.5% total return over the past five years, yet its current checks send a mixed valuation message, with an intrinsic value estimate based on the Excess Returns model pointing to upside while traditional earnings multiples lean the other way. A 137.5% gain over five years puts Apollo Global Management firmly in the group of stocks that have already rewarded long term holders, which can make fresh entries more sensitive to what happens next in...

Class action lawsuits and legal investigations are now front and center for ADMA Biologics (ADMA), after several law firms alleged securities fraud related to related party transactions, channel stuffing, and disclosures about business practices. See our latest analysis for ADMA Biologics. At a latest share price of $9.90, ADMA Biologics has seen a 7 day share price return of 17.02% and a 90 day share price return of 21.18%, yet the year to date share price return is down 44.63%. Over the...

T-Mobile US recently launched new “Experience 2.0” and “Essentials 2.0” plans that add 36‑month Equipment Installment Plan options, including EIP Flex 36, allowing well-qualified customers to finance devices, taxes and fees with nothing due at checkout, alongside discounted Student Perks plans and 5G Home Internet bundles with prepaid card rebates of up to US$200. By shifting more customers toward longer-term device financing and targeted student offers, T-Mobile is reshaping how upfront...

Flowers Foods (FLO) has drawn investor attention after its share price closed at $7.40 on 4 September 2024, with the stock showing mixed shorter term returns and a weaker longer term profile. See our latest analysis for Flowers Foods. For context, the recent rebound in Flowers Foods, with a 1-day share price return of 2.21% and a 7-day share price return of 5.41%, comes after a much weaker backdrop. This includes a 30-day share price return down 11.59% and a 1-year total shareholder return...

In late July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue rising to US$204.13 million while net income and earnings per share fell compared with a year earlier, and confirmed no share repurchases during the quarter under its existing buyback authorizations. The earnings release highlighted a contrast between growing top-line demand and pressure on profitability, offering fresh insight into how Repligen’s current cost structure and product mix are affecting...

Kilroy Realty’s late-July 2026 quarterly update showed lower second-quarter and year-to-date revenues and net income, while management reaffirmed full-year 2026 earnings guidance and detailed ongoing capital allocation moves, including completion of a US$72.62 million share repurchase and a US$66.997 million ESOP-related shelf registration for 1,700,000 shares. Alongside these results, executives highlighted a more active transaction landscape on the West Coast, with Kilroy carefully...

Niagen Bioscience (NAGE) has moved back into the spotlight after two recent developments. A peer reviewed analysis highlighted Niagen supplementation’s impact on muscle epigenetic age acceleration, while Tru Niagen’s launch on Walmart.com expands its healthy aging reach. See our latest analysis for Niagen Bioscience. Recent announcements around Niagen Bioscience, including the peer reviewed muscle aging study and Tru Niagen’s Walmart.com debut, come after a challenging share price stretch...

SPS Commerce, Inc. recently reported past second-quarter 2026 results, with sales rising to US$197.82 million while net income and diluted EPS from continuing operations fell to US$6.86 million and US$0.19, respectively, and also updated guidance calling for full-year 2026 revenue of US$788.4 million to US$793.4 million. Alongside these results, the company completed a US$113.64 million buyback equal to 4.93% of shares, signaling a meaningful capital return alongside expectations for revenue...

RM-718 trial data puts Rhythm Pharmaceuticals (RYTM) pipeline in focus Rhythm Pharmaceuticals (RYTM) has drawn fresh investor attention after releasing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing double digit mean BMI reductions and a generally well tolerated safety profile. See our latest analysis for Rhythm Pharmaceuticals. The RM-718 update has arrived alongside a sharp pickup in Rhythm Pharmaceuticals' share price momentum, with a 7-day share price return...

Why Avantor Raised Full Year Guidance After Q2 Results Avantor (AVTR) raised its full year guidance after returning to organic growth in its distribution business, with the VWR segment showing earlier than expected improvement and the Revival program delivering measurable operational progress. The updated outlook follows second quarter 2026 earnings, where Avantor reported sales of US$1,692.3 million and net income of US$38.1 million, alongside modestly higher first half sales and lower net...

Sea Limited has moved back into focus this week as investors react to recent trading volatility and look ahead to its 11 August 2026 earnings release, with consensus pointing to year-over-year gains in both earnings per share and revenue across e-commerce and digital entertainment. Behind the headlines, the key tension is between upbeat growth expectations and mounting concern that heavier spending and higher credit loss provisions could weigh on profitability. Next, we’ll examine how this...

Berkshire Hathaway has quietly flipped the script in Q2 2026, shifting from record cash reserves to heavier investing and buybacks, and that ripple is now reaching individual stocks. This change in behaviour can open up pockets of opportunity and pockets of risk for investors who pay attention. This article walks through three stocks exposed to the same forces, two potential beneficiaries and one possible loser, to help you decide where to lean in and where to be cautious. Allstate...

Tilray Brands (TLRY) just rolled out Mollo Lite Blackberry Lemon Seltzers as its first light THC beverage multipack in Canada, putting fresh attention on how the stock reflects its cannabis beverage platform. See our latest analysis for Tilray Brands. The new Mollo Lite launch lands after a mixed run for Tilray Brands, with a 1-day share price return of 2.93% to US$4.57 and a 30-day share price return of 4.10%, but a year-to-date share price decline of 52.98% and a 5-year total shareholder...

Earnings and Guidance Update Put CONMED Stock in Focus CONMED (CNMD) drew fresh attention after reporting second quarter 2026 results, with net income and earnings per share higher than a year earlier and a modestly raised full year net sales outlook. See our latest analysis for CONMED. The latest earnings and modest guidance lift have come alongside a sharp shift in sentiment, with CONMED’s share price up 46.23% over the past month. However, the 1 year total shareholder return is still down...

What LivaNova’s latest earnings mean for the stock now LivaNova (NasdaqGS:LIVN) released second quarter 2026 results that showed higher sales and a shift from last year’s loss to net income, which quickly put the stock back on many investors’ radars. See our latest analysis for LivaNova. LivaNova’s strong second quarter has landed on top of a share price that is now US$76.22, with a 1 year to date share price return of 25.69% and a 1 year total shareholder return of 56.06%, suggesting...

Buckle (BKE) shares are in focus after the retailer reported higher comparable store net sales and total net sales across the latest 4-week, second-quarter, and year-to-date periods. See our latest analysis for Buckle. The trading update appears to have shifted sentiment around Buckle, with the share price up 10.81% over the past month but still down 14.70% year to date on a share price return basis. The 5 year total shareholder return of 71.46% shows the longer term picture. If Buckle’s...

In the second quarter of 2026, Tronox Holdings plc reported sales of US$868 million, up from US$731 million a year earlier, while its net loss widened to US$171 million and the Board maintained a US$0.05 quarterly dividend. The company’s guidance for a mid-single-digit moderation in third-quarter production volumes and the appointment of audit veteran Keith Schwarz to the Board highlight a focus on managing seasonal demand patterns while reinforcing financial oversight amid ongoing...

Kulicke and Soffa Industries (KLIC) stock is back in focus after the company reported strong third quarter results, issued higher revenue and earnings guidance, and confirmed progress on capacity expansion in key advanced packaging areas. See our latest analysis for Kulicke and Soffa Industries. Against this backdrop, Kulicke and Soffa Industries’ recent earnings beat and higher guidance have come after a sharp reset. The 30 day share price return is 12.4% and the 90 day share price return is...

Bio-Rad Laboratories stock has rebounded in the short term, yet the current price around US$352 still screens as expensive relative to its intrinsic value estimate and market multiples. After a 5 year period where the share price fell 54.7%, the recent strength sits against valuation checks that point to a premium rather than a clear bargain. Over the last 5 years, Bio-Rad Laboratories is down 54.7%, which suggests long term holders have taken a significant hit even though the recent share...

With the June 2026 CPI print landing just weeks before a key Federal Reserve meeting, interest rate expectations are again front and center for anyone watching US real estate stocks. Rate sensitive property companies can see their borrowing costs and valuations shift quickly when inflation surprises. This article breaks down how that backdrop connects to three stocks from a US Rate Sensitive Real Estate screener and why their reactions could matter for your portfolio. The three stocks below...

Thermo Fisher Scientific event puts specialty diagnostics in focus Thermo Fisher Scientific (TMO) has put its specialty diagnostics business in the spotlight after showcasing new products and recent U.S. Food and Drug Administration clearances at the ADLM conference in Anaheim in late July 2026. The event highlighted the EXENT Solution for multiple myeloma monitoring and the EliA CTD 13 Screen for autoimmune disease testing, along with software and quality control tools designed to support...